Ascentage Pharma股价下跌5.5%，空头几乎为零，分析师支持强劲。 Ascentage Pharma shares fell 5.5% amid near-zero short interest and strong analyst support.

Ascentage Pharma（NASDAQ：AAPG）股价周一下跌至27.70美元，跌幅5.5%，主要因交易量低迷，此前空头量大幅下降——截至12月15日下跌84.2%，至254股，且无空头。 Ascentage Pharma (NASDAQ:AAPG) shares dipped to $27.70 on Monday, down 5.5%, on low trading volume, following a sharp decline in short interest—down 84.2% to 254 shares by December 15, with no shares short sold. 股票在星期三交易27.88美元,分析师保持“Buy”评级,目标为48.50美元。 The stock traded at $27.88 on Wednesday, with analysts maintaining a "Buy" rating and a $48.50 target. 该公司正在开发诸如APG-2575和APG-115等癌症疗法,其债务与股本比率为1.31,流动性比率很高。 The company, developing cancer therapies like APG-2575 and APG-115, has a debt-to-equity ratio of 1.31 and strong liquidity ratios.